EBR aligns with FDA on proactive safety labelling update for WiSE System
EBR Systems has announced a plan to submit a Changes Being Effected (CBE) Premarket Approval (PMA) supplement to the FDA in Q4 2026, targeting a proactive update to commercial labelling for its WiSE® System. The update is designed to elevate the visibility of echo-induced pacing risk and the mitigation strategies implanters can use to prevent known complications.
The submission represents a deliberate, proactive effort by EBR to strengthen procedural guidance as the commercial rollout of the WiSE System continues to scale across the US.
When big ASX news breaks, our subscribers know first
What the CBE PMA Supplement means and why the regulatory pathway matters
A Changes Being Effected (CBE) PMA Supplement is a streamlined FDA regulatory pathway specifically suited to labelling improvements. It differs from a standard PMA Supplement in one significant respect: labelling enhancements can be implemented without requiring prior FDA approval, while the submission remains under review.
Key features of the CBE pathway:
- Allows safety enhancements to be implemented before the FDA completes its formal review
- Designed for targeted updates that do not alter the device’s fundamental design or function
- Preferred for labelling changes because it avoids commercial disruption during the review period
Echo-induced pacing risk refers to a known complication that can arise during cardiac device implantation, where acoustic energy from an echocardiogram inadvertently triggers unintended pacing. Clear labelling around mitigation strategies ensures implanters have prominent, accessible guidance to prevent this before it occurs.
For investors, the regulatory pathway choice matters. FDA alignment, rather than pushback, removes a potential overhang on EBR’s US commercial scale story. A CBE submission keeps the rollout moving while the regulatory process runs concurrently.
The CBE submission fits a pattern of EBR resolving FDA regulatory overhang proactively rather than reactively, a posture that has characterised the company’s interactions with regulators throughout its US commercial scale-up.
CEO commentary and the patient safety commitment
John McCutcheon, President & Chief Executive Officer
“As the commercial adoption of the WiSE System gathers momentum across the US, our paramount commitment remains patient safety and procedural success. This proactive labelling update ensures that the clinical mitigations we have developed are clearly visible and top-of-mind for implanters, empowering them the mitigate complication before they occur.”
The FDA meeting resulted in full alignment on the path forward. EBR addressed FDA questions during the meeting, and the FDA raised no objections to the plan. EBR described the interaction as collaborative, reflecting management’s approach to proactive governance during a period of active commercial scaling.
WiSE System commercial context and what comes next
The WiSE System is the world’s only wireless, endocardial left ventricle pacing system currently available for sale in the US. The implant is roughly the size of a large grain of rice and is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Eliminating pacing leads potentially removes a historically significant source of complications, effectiveness, and reliability issues in cardiac rhythm disease management.
Investors watching the EBR commercial story should track the following milestones:
The labelling update sits alongside a larger reimbursement catalyst: a CMS National Coverage Determination review that could establish national Medicare coverage for eligible WiSE patients by March 2027, materially expanding the addressable population if confirmed.
- Q4 2026: Planned CBE PMA Supplement submission to the FDA
- Post-submission: FDA review outcome for the labelling update
- Continued US commercial rollout momentum for the WiSE System
EBR’s broader mission centres on addressing cardiac rhythm disease through wireless pacing technology, with future products potentially targeting wireless endocardial stimulation for bradycardia and other non-cardiac indications.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.